The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Category Archives: Jacob Cawker

Canadian Biotech and Healthcare Licensing Trends in 2010

I was fortunate this week to host the Canadian Healthcare Licensing Association‘s (CHLA’s) annual holiday get-together on behalf of Ogilvy Renault at our Toronto office (we hosted a parallel CHLA event in Montreal earlier this week). I presented a short slide deck on licensing trends in 2010, with data drawn from our Monday Biotech Deal Reviews and from Wayne Schnarr’s quarterly reports. For your viewing enjoyment,the slideshare version is below. You can also download a pdf of the presentation here.

Monday Biotech Deal Review: November 29, 2010



Welcome to your Monday Biotech Deal Review.  I hope our American readers had a very happy thanksgiving weekend, but hopefully there’s still some room left for your weekly digest of biotech deals.  This week witnessed the closing of the US$52M IMRIS financing [Ed. -- as well as a rafter of other deals].  Read on to learn more about these and other deals from the previous week.  Read more of this post

Monday Biotech Deal Review: November 22, 2010

Welcome to your Monday Deal Review.  There was quite a bit of Canada / U.S. crossborder investment activity last week, with a $700M note offering by Valeant, IMRIS’ USD$52M public offering, and both IMRIS and Tekmira announcing their listing on the NASDAQ.   Read on to learn more, as well as the usual summaries of recent biotech activity. Read more of this post

Biotech in the Provinces: OBEST Launches Regional Meetings in Ontario; Western Canada Innovation Agreement to Provide Seed Funding

The Ontario Bioscience Economic Strategy Team (OBEST)* is holding regional cluster meetings starting today that will be chaired by bioscience CEOs from across the province. OBEST launched its evergreen strategy to sustain and grow the province’s health-science industry last week with a meeting of the OBEST advisory committee, which is chaired by Dr. Daniel Billen from Amgen Canada, and includes C-level representatives from business, patient groups, government, academia, ag-biotech and Ontario’s biotech companies.

Innovative ideas are being sought from everyone with a stake in the industry via the regional cluster meetings, which will inform the Advisory Committee’s work.

Meanwhile, out West, the Centre for Drug Research and Development, together with the Provinces of British Columbia and Alberta, and Johnson & Johnson Corporate Office of Science and Technologywill administer a fund supporting innovative health research programs, called the Western Canada Innovation Agreement.  The seed funding will enable early-stage discoveries to achieve commercialization in the life sciences sector.  For more information, visit www.jnjcosat.com/cosat.

* OBEST is an initiative of OBIO, where I am the corporate secretary.

Monday Biotech Deal Review: November 15, 2010

Welcome to the Monday Biotech Deal Review for November 15, 2010.  Read on to learn about IMRIS’ proposed U.S. IPO, a mysterious merger in the making, and heart lasers (and how much they go for), together with your usual assortment of private placements, announcements and other biotech news.  Read more of this post

Monday Deal Review: November 8, 2010

Welcome to your Monday Deal Review.  The Canadian biotech sector was fairly busy this week, with approximately $17M in investment money flowing into biotech companies reviewed below.  Valeant is certainly raking the leaves this fall following the Biovail merger, settling lawsuits, entering a $1.5bn securities repurchase program, and entering strategic agreements this week after ending a collaboration last week.  Read on to learn more, as well as the usual assortment of biotech news.  Read more of this post

Monday Deal Review: November 1, 2010

Welcome to the Monday Deal Review for November 1, 2010.  This week’s review contains the news of a possible recapitalization of Angiotech, following its deferral of interest payments on 7.75% Senior Subordinated Notes due October 1, 2010.  Read on to learn more, as well as other happenings from last week’s biotech scene. Read more of this post

Monday Biotech Deal Review: October 25, 2010

Welcome to your weekly review of Canadian biotech deals for October 25, 2010.  Last week’s notable transactions included the Qualifying Transaction of TSXV CPC company CCS Capital Inc. (now known as China Health Labs & Diagnostics Ltd.) and ProMetic’s strategic agreement with Allist Pharmaceuticals Inc., for the commercialization in China of two of ProMetic’s drug candidates.  Read on to learn more about these transactions, as well as the usual assortment of Canadian biotech news. Read more of this post

Monday Biotech Deal Review: October 18, 2010

Despite the short week, it was a busy one in the Canadian biotech sector. Read on to learn about the Labopharm / Paladin licensing deal, Ondine’s new facelift (and 15:1 equity liposuction), and various other biotech updates and news. 

Read more of this post

Monday Biotech Deal Review: October 11, 2010

Happy (Canadian) Thanksgiving!  This Monday Biotech Deal Review reports that it was a bad week for turkeys and a bit of a slow week on the biotech front, but read on to learn about some interesting collaborations, allegations and corporate immigrations. Read more of this post

Monday Biotech Deal Review: October 4, 2010

This week’s Monday Deal Review brings you the usual assortment of biotech wheelings and dealings from the past week, including a summary of the newly completed Valeant / Biovail merger.  Read more of this post

Monday Biotech Deal Review: September 27, 2010

Welcome to your Monday Biotech Deal Review. I am very excited to be writing for The Cross-Border Biotech Blog after working with Jeremy behind the scenes over the past three years. [ed. welcome (back) aboard!] It was a busy week for Canadian biotech companies, so let’s get started. Read more of this post

Cross-Border Biotech Blog News: Favourite Features Returning With New Authors

I’m excited to announce that the Monday Biotech Deal Review and the Friday Science Review will be back next week to restart your regular dosing of Canada’s Biotech inventions and transactions.

The Monday Deal Review will be authored by Jacob Cawker, who has worked with me on the blog in various capacities over the past three years. Jake recently joined Ogilvy Renault LLP as an associate in the Business Law group, and will be part of our Life Sciences transactional team.  He has an Honours Bachelor of Science from the University of Toronto at Mississauga with a specialist in Psychology and a particular interest in neuroscience, and he worked in a behaviour genetics lab at the University of Toronto before entering law school at Osgoode Hall University.

The Friday Science Review will be authored by Mark Curtis, who recently left scientific research to pursue various consulting positions in the biotechnology sector. He has frequently worked as a consultant to Bloom Burton & Co., a boutique investment bank in Toronto that focuses exclusively on the biotechnology and healthcare industries. Prior to this he carried out research at the Ontario Cancer Institute where he focused on cellular reprogramming of human cells. Mark completed a Master’s degree in Biotechnology, with a specialization in stem cell biology, at the University of New South Wales in Sydney, Australia.

Follow

Get every new post delivered to your Inbox.

Join 126 other followers